1. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates
- Author
-
Du, Yuanyuan, Liang, Zhen, Wang, Shusen, Sun, Dong, Wang, Xiaofeng, Liew, Soon Yi, Lu, Shuaiyao, Wu, Shuangshuang, Jiang, Yong, Wang, Yaqi, Zhang, Boya, Yu, Wenhai, Lu, Zhi, Pu, Yue, Zhang, Yun, Long, Haiting, Xiao, Shanshan, Liang, Rui, Zhang, Zhengyuan, Guan, Jingyang, Wang, Jinlin, Ren, Huixia, Wei, Yanling, Zhao, Jiaxu, Sun, Shicheng, Liu, Tengli, Meng, Gaofan, Wang, Le, Gu, Jiabin, Wang, Tao, Liu, Yinan, Li, Cheng, Tang, Chao, Shen, Zhongyang, Peng, Xiaozhong, and Deng, Hongkui
- Abstract
Human pluripotent stem-cell-derived islets (hPSC-islets) are a promising cell resource for diabetes treatment1,2. However, this therapeutic strategy has not been systematically assessed in large animal models physiologically similar to humans, such as non-human primates3. In this study, we generated islets from human chemically induced pluripotent stem cells (hCiPSC-islets) and show that a one-dose intraportal infusion of hCiPSC-islets into diabetic non-human primates effectively restored endogenous insulin secretion and improved glycemic control. Fasting and average pre-prandial blood glucose levels significantly decreased in all recipients, accompanied by meal or glucose-responsive C-peptide release and overall increase in body weight. Notably, in the four long-term follow-up macaques, average hemoglobin A1c dropped by over 2% compared with peak values, whereas the average exogenous insulin requirement reduced by 49% 15 weeks after transplantation. Collectively, our findings show the feasibility of hPSC-islets for diabetic treatment in a preclinical context, marking a substantial step forward in clinical translation of hPSC-islets.
- Published
- 2022
- Full Text
- View/download PDF